Dapagliflozin

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Dapagliflozin
   1. Pharmacist Assessment Report
   2. Dapagliflozin
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Dapagliflozin

Summary

The TxGNN deep-learning model has no candidate indication with a score of 0.99 or higher for Dapagliflozin, so there is currently no new predicted indication. The drug’s recorded uses are listed below. They are the drug’s own recorded uses, not model candidates.

Quick overview

Item	Content
Known uses recorded for this drug	8
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
chronic renal insufficiency	licence in another country
diabetes	licence in another country
diabetes mellitus, type 2	licence in another country
heart failure	licence in another country
systolic heart failure	licence in another country
type 2 diabetes	licence in another country

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
diabetes mellitus
type 2 diabetes mellitus

Australia Market Information

Licence	Product	Dosage form	Status
10011X	Forxiga	Tablet 10 mg (as propanediol monohydrate	Valid

Safety Considerations

Drug Interactions: The interaction screen returned 100 interacting drugs in total, and the 20 shown here are mainly of moderate severity. Examples include:

• Diuretics and antihypertensives (furosemide, hydrochlorothiazide, acetazolamide, nifedipine, aliskiren, fosinopril, acebutolol, alfuzosin)
• Sympathomimetics and bronchodilators (phenylephrine, pseudoephedrine, epinephrine, salbutamol, formoterol)
• Corticosteroids (hydrocortisone, moderate; topical hydrocortisone and topical alclometasone, minor)
• Others (ethanol, levonorgestrel, fosamprenavir, gemifloxacin)

Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---